EGFR and non-small cell lung carcinoma: The FLAURA study, which received wide attention at the 2019 European Society for Medical Oncology (ESMO) congress, confirmed that EGFR-mutant NSCLC patients treated with the third-generation EGFR-TKI osimertinib [5] had a 6.8 months prolongation of overall survival (OS) compared to patients receiving gefitinib or erlotinib therapy [6].